Weight Loss Drugs Weight Loss Studies Weight Loss Patient Outcomes ESSENCE Trial Cardiovascular Health Phase 3 Trials Lenacapavir Studies Phase Trials Dosing Strategies FDA Approval Orforglipron Antiretroviral Drugs Regulatory Challenges Linzagolix Anti-fibrotic Treatments Toxicity Studies Mounjaro Trials Biomarkers Preventive Treatments Weight Loss Treatments Ruxolitinib Infection Prevention Safety Profile Medical Needs Type 1 Diabetes Treatment Compounded Medications Research Studies Survival Rates Breakthrough Therapy Designation HIV Research SERENA-6 Study GLP-1 Therapies Ozempic Trials BCR::ABL1 Inhibitors Medical Results Safety and Tolerability
The move secures global rights to experimental drug sevasemten and positions Servier to expand in rare neurology with closing expected in Q3 2026 pending regulatory clearance.
